Rationale for early treatment with interferon beta-1a in relapsing- remitting multiple sclerosis

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 868-882

  Munschauer III, Frederick E ^a,c   Stuart, William H ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b SHEPHERD CENTER   (United States)

^c William C Baird Multiple S ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON;

DISEASE COURSE; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PROGNOSIS; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; RISK FACTOR;

EID: 0030664024     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80041-0     Document Type: Article

References (36)

1. Tolley KH, Whynes DK. Interferon-beta in multiple sclerosis. Can we control its costs? Pharmacoeconomics. 1997; 11: 210-215.
2. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain. 1989; 112: 133-146.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol. 1996; 39:285-294.
4. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907-911.
5. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin. 1995;13: 119-146.
6. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116(Pt 1):117-134.
7. Minderhoud JM, van der Hoeven JH, Prange AJ. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand. 1988;78:10-15.
8. Poser CM, Paty DW, Scheinberg LS, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983;13:227-231.
9. Rolak LA. The diagnosis of multiple sclerosis. Neurol Clin. 1996;14:27-43.
10. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci. 1987;14:255-261.
11. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: A geographically based study. II. Predictive value of the early clinical course. Brain. 1989;112:1419-1428.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
13. Goodkin DE. The natural history of multiple sclerosis. In: Rudick RA, Goodkin DE, eds. Treatment of Multiple Sclerosis: Trial Design, Results, and Future Perspectives. London: Springer-Verlag; 1992; 17-45.
14. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: A critique. Neurology. 1988;38:1793-1798.
15. Muller R. Studies on disseminated sclerosis with special reference to symptomatology, course and prognosis. Acta Med Scand. 1949;222(Suppl):1-214.
16. McAlpine D, Compton N. Some aspects of the natural history of disseminated sclerosis. Part 1. The incidence, course, and prognosis. Part 2. Factors affecting the onset and course. Q J Med. 1952;21: 135-160.
17. Panelius M. Studies on epidemiological, clinical and etiological aspects of multiple sclerosis. Acta Neurol Scand. 1969;45 (Suppl)39:1-82.
18. Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology. 1992;42:859-863.
19. Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of COP I in chronic progressive multiple sclerosis. Neurology. 1991;41:533-539.
20. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45:1268-1276.
21. Johnson KP, Knobler RL, Greenstein JI, et al. Recombinant human beta interferon treatment of relapsing-remitting multiple sclerosis: Pilot study results. Neurology. 1990;40(Suppl 1):261. Abstract.
22. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
23. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis. Final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
24. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology. 1992;42:991-994.
25. Filippi M, Miller DH. Magnetic resonance imaging in the differential diagnosis and monitoring of the treatment of multiple sclerosis. Curr Opin Neurol. 1996;9: 178-186.
26. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history. Ann Neurol. 1991;29:548-555.
27. 2-weighted brain MRI activity in multiple sclerosis: A follow-up study. Neurology. 1995;45:255-260.
28. McFarland HF, Stone LA, Calabresi PA, et al. MRI studies of multiple sclerosis: Implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler. 1996;2:198-205.
29. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993;33:480-489.
30. Stone LA, Smith ME, Albert PS, et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and age. Neurology. 1995;45:1122-1126.
31. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain. 1997;120(Pt 5):865-916.
32. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Neurology. 1997; 49:358-363.
33. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:662-667.
34. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995;37:611-619.
35. Okagaki JF. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1994;44:1537-1540.
36. Munschauer FE, Kinkel RP. Managing side effects of interferon-beta in patients with remitting-relapsing multiple sclerosis. Clin Ther. In press.